Signature Formulations' CBD Products Meet FDA Drug Policy On Claims, GMPs

Malcolm Spicer

首页> 外文期刊>The Rose Sheet: Toiletries, Fragrances and Skin Care >Signature Formulations' CBD Products Meet FDA Drug Policy On Claims, GMPs

【24h】

Signature Formulations' CBD Products Meet FDA Drug Policy On Claims, GMPs

机译：标志性配方的CBD产品符合FDA药物政策的索赔，GMP

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

FDA's warning letter to Phoenix firm lists violations of the agency's GMP regulations for drug products found in an October-November 2017 inspections in addition to identifying violative claims for its balms, creams, gels, oils, salves and toothpastes containing CBD and other botanicals.

机译：FDA给菲尼克斯公司的警告函列出了违反了原子能机构的GMP法规，除了识别含有CBD等植物和其他植物的植物，奶油，凝胶，油，酱油和牙膏的违规索赔外，还违反了美国药品的GMP规定。

著录项

来源
《The Rose Sheet: Toiletries, Fragrances and Skin Care 》 |2018年第33期| 共4页
作者
Malcolm Spicer;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类香料及化妆品工业 ;
关键词

相似文献

外文文献
中文文献
专利

1. Signature Formulations' CBD Products Meet FDA Drug Policy On Claims, GMPs [J] . Malcolm Spicer The Rose Sheet: Toiletries, Fragrances and Skin Care . 2018 ,第33期

机译：标志性配方的CBD产品符合FDA药物政策的索赔，GMP
2. FDA Gives Herbal Healer Academy Lesson On CBD, GMPs, Labels, Homeopathics [J] . MALCOLM SPICER The Rose Sheet: Toiletries, Fragrances and Skin Care . 2019 ,第39期

机译：FDA在CBD，GMP，标签，顺势疗法中给中草药治疗师学院课程
3. "Our products meet all stringent cGMP/FDA requirements" [J] . Matteo Forlenza Chemical Engineering World . 2008 ,第6期

机译：“我们的产品符合所有严格的cGMP / FDA要求”
4. Drug Piracy II: Quality, Efficacy and Safety Issues Related to Drug-Pirated Products ("compounded drug") and the Claims Associated with Them [C] . Joseph J. Bertone Annual Conference of American Association of Bovine Practitioners . 2004

机译：药物盗版二：与药物盗版产品（“复合药物”）和与他们相关的索赔有关的质量，疗效和安全问题
5. Evaluation of three statistical estimation procedures in the assessment of the association between the fda suicidality warning and antiepileptic drug prescription claims in a state medicaid program. [D] . Mittal, Manish. 2013

机译：在州医疗计划中，对fda自杀性警告与抗癫痫药处方要求之间的关联进行评估时，采用三种统计估计程序进行评估。
6. Midyear Commentary on Trends in Drug Delivery and Clinical Translational Medicine: Growth in Biosimilar (Complex Injectable Drug Formulation) Products Within Evolving Collaborative Regulatory Interagency (FDA FTC and DOJ) Practices and Enforcement [O] . Rodney J.Y. Ho -1

机译：年中对药物输送和临床转化医学趋势的评论：不断发展的合作监管机构（FDAFTC和DOJ）实践和执行中生物仿制药（复杂的可注射药物制剂）产品的增长
7. PMC55 IMPACT OF THE FDA DRAFT GUIDANCE ON PATIENT REPORTED OUTCOMES (PRO) LABEL CLAIMS FOR APPROVED DRUG PRODUCTS IN THE US: HAS IT MADE A DIFFERENCE? [O] . Mordin M, Clark M, Siersma C, 2009

机译：FDA指导草案对美国批准的药物产品的患者报告结果（PRO）标签索赔的影响：有何不同？

Signature Formulations' CBD Products Meet FDA Drug Policy On Claims, GMPs

摘要

著录项

相似文献

相关主题

期刊订阅